Hofseth BioCare plans NOK 125 million-175 million private placement at NOK 1.3/share

  • Hofseth BioCare launched a private placement of 96,153,846 to 134,615,384 new shares at NOK 1.3 each.
  • Deal targets gross proceeds of about NOK 125 million to NOK 175 million; NOK 127.2 million already covered by binding pre-commitments.
  • Settlement combines cash with conversion of receivables; about NOK 66.5 million expected to be paid via debt conversion.
  • Proceeds earmarked for growth capital, balance sheet strengthening, general corporate purposes.
  • Two-tranche structure; Tranche 2 requires an EGM around July 30, 2026, with delivery expected around Aug. 5, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hofseth BioCare ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606261055OMX_____CNEWS_EN_GNW1001209842_en) on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.